Kiniksa Pharmaceuticals, Ltd. has announced the pricing of its public offering of 5,952,381 Class A common shares at a public offering price of US$21 per share, before underwriting discounts and commissions. The gross proceeds to Kiniksa from this offering, together with the proceeds of the sale of 1,428,572 Class A1 common shares in a concurrent private placement under Section 4(a)(2) of the Securities Act of 1933, before fees and estimated expenses, are expected to be approximately US$155 million. In addition, Kiniksa has granted the underwriters a 30-day option to purchase up to 892,857 additional Class A common shares at the public offering price, less underwriting discounts and commissions. The public offering is expected to close on July 24, 2020, subject to customary closing conditions. All of the Class A common shares are being offered by Kiniksa.
Latham & Watkins LLP represented Kiniksa Pharmaceuticals in the offering with a capital markets team led by New York partner Nathan Ajiashvili, with associates Jennifer Yoon, Andrew Weitzel, and Emily Henderson.